Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer

Journal of Thoracic Disease
Tamer SororHarun Badakhshi

Abstract

Neoadjuvant radiochemotherapy (nRCT) followed by surgery has become the gold standard treatment in patients with locally advanced esophageal cancer. The pathological response is an important predictor in such patients. This work represents a single-center analysis investigating the impact of pathological complete response (pCR) on treatment outcome. All patients treated with nRCT followed by surgery between January 2005 and December 2015 were reviewed. The patients were categorized into two groups according to the pathological response following nRCT: pCR group and non-pCR group. Fifty-six patients with invasive cancer, 23 patients (41.1%) achieved pCR and 33 patients had non-pCR (58.9%) following nRCT. The average age was 62 years (±9.1), and most patients were males (83.9%). Histological types included squamous cell carcinoma (75%) and adenocarcinoma (25%). The total radiation dose was 45 Gy in 76.8% of the patients and 50.4 Gy in 23.2%. The median overall survival (OS) of the entire group was 3.5±1.2 years, and the 5-year OS rate was 38.2%, while the median disease-free survival (DFS) was 2.1±0.4 years and the 5-year DFS rate was 33.1%. The patients who achieved pCR had significantly higher 5-year OS and 5-year DFS rates: 47...Continue Reading

Citations

Feb 17, 2019·Annals of Surgical Oncology·Kimberly J Song, Andrew T Arndt
Jun 27, 2019·Journal of Gastrointestinal Cancer·Guilherme HaradaTiago Biachi de Castria
Nov 30, 2020·Annals of Surgical Oncology·Helena Hong WangUNKNOWN Dutch Upper Gastrointestinal Cancer Audit (DUCA) Group
Apr 25, 2021·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Eliza HagensSheraz R Markar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.